UNSPSC 51162027: Ephedrine/phenobarbital/theophylline

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE109. This VA Drug Class (RE109) classifies this compound as belonging to the group ANTIASTHMA, OTHER.

UNSPSC 51162027 Ephedrine/phenobarbital/theophylline is a Commodity code that encompasses pharmaceutical products and pharmacy services, though recent state and local opportunities under this code show significant scope misalignment—the solicitations tag naloxone delivery systems, on-site employer pharmacy services, direct-to-manufacturer prescription programs, and generic pharmaceutical distribution through cooperative purchasing, none of which directly align with the code's nominal focus on specific bronchodilator and stimulant medications. State and local governments are actively procuring pharmacy-related goods and services under this code, spanning health departments, county government health centers, state health and human services agencies, and multistate cooperative purchasing alliances. The issuing bodies include county health departments and government health clinics serving employee populations, state-level health agencies managing prescription benefit programs, and large cooperative purchasing vehicles such as MMCAP that aggregate demand across multiple jurisdictions.

Recent activity shows geographic spread across Florida, Georgia, Texas, and Minnesota, with the most developed opportunities emerging from county-level health services and state cooperative purchasing. Representative recent opportunities include Seminole County, Florida's IFB 60459723LAS seeking 1,900 units of naloxone and 800 drug deactivation systems annually with a response deadline of July 26, 2023 (note: the solicitation posting date of June 30, 2026 conflicts with the response deadline of 2023; the opportunity document shows material dating inconsistencies); Hall County, Georgia's RFQ/P #47-010 for on-site pharmacy services at the Family Health Center Clinic with a June 4, 2026 deadline, evaluated on an 80/20 technical-to-cost basis with an initial one-year term and four optional renewal years; the Texas Health and Human Services Commission's RFI HHS0017013 for Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions posted April 3, 2026 as a market-intelligence effort preceding formal procurement; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, distributed through authorized wholesalers and effective July 1, 2026. The code shows activity but lacks consistent relevance to its stated pharmaceutical scope across recent postings.